The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
Despite a growing understanding of the pathogenesis and spectrum of Epstein-Barr virus (EBV) and EBV-associated post-transplant lymphoproliferative disease (PTLD) in organ transplant recipients, the optimal management of this complication remains controversial. The absence of comparative data evaluating potential therapeutic strategies explains the lack of uniformly accepted guidelines for the management of PTLD. The purpose of this review is to provide an overview of potential therapies and offer a set of guidelines for the management of EBV-associated PTLD in children.
Green
M
M
Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Pittsburgh, Pennsylvania, USA.
Michaels
M G
MG
Webber
S A
SA
Rowe
D
D
Reyes
J
J
D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D004279:DNA, Viral / Q000032:analysis; D004359:Drug Therapy, Combination; D020031:Epstein-Barr Virus Infections / Q000473:pathology / Q000628:therapy* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000473:pathology / Q000628:therapy* / Q000821:virology; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000473:pathology / Q000628:therapy* / Q000821:virology; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D004279:DNA, Viral; D007166:Immunosuppressive Agents; D007372:Interferons